Search

Displaying results 1291 - 1300 of 4344 in total
  1. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial

  2. Drug

    Hyaluronidase (ovine)

    go.drugbank.com/drugs/DB00070
    Approved

    Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.

  3. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It was developed by The Medicines Company (acquired by Novartis). … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629]

  4. Drug

    Streptokinase

    go.drugbank.com/drugs/DB00086
    ApprovedInvestigationalWithdrawn

    Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

  5. Drug

    Sodium ferric gluconate complex

    go.drugbank.com/drugs/DB09517
    Approved

    Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons...

  6. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  7. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. … [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  8. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.

  9. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. … Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

  10. Drug

    Bexarotene

    go.drugbank.com/drugs/DB00307
    ApprovedInvestigational

    Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.